ATP150
/ Boehringer Ingelheim
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 18, 2025
KISIMA-02: A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma
(clinicaltrials.gov)
- P1 | N=94 | Recruiting | Sponsor: Amal Therapeutics | Trial completion date: Mar 2027 ➔ May 2029 | Trial primary completion date: Dec 2026 ➔ Jun 2028
Trial completion date • Trial primary completion date • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • KRAS
November 29, 2023
A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)
(clinicaltrials.gov)
- P1 | N=85 | Recruiting | Sponsor: Amal Therapeutics | Phase classification: P1b ➔ P1
Phase classification • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • KRAS
May 06, 2023
A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)
(clinicaltrials.gov)
- P1b | N=85 | Recruiting | Sponsor: Amal Therapeutics
New P1 trial • Gastrointestinal Cancer • Immune Modulation • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • KRAS
1 to 3
Of
3
Go to page
1